Vertex Pharmaceuticals Incorporated (VRTX)

Basic

  • Market Cap

    $91.21B

  • EV

    $78.32B

  • Shares Out

    257.68M

  • Revenue

    $9,654.2M

  • Employees

    4,800

Margins

  • Gross

    61.6%

  • EBITDA

    47.34%

  • Operating

    45.67%

  • Pre-Tax

    44.63%

  • Net

    35.94%

  • FCF

    43.56%

Returns (5Yr Avg)

  • ROA

    14.89%

  • ROE

    35.29%

  • ROCE

    28.51%

  • ROIC

    75.44%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $395.9

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $37.49

  • Earnings (Dil)

    $13.32

  • FCF

    $16.15

  • Book Value

    $64.05

Growth (CAGR)

  • Rev 3Yr

    17.24%

  • Rev 5Yr

    27.82%

  • Rev 10Yr

    23.24%

  • Dil EPS 3Yr

    9.29%

  • Dil EPS 5Yr

    39.7%

  • Dil EPS 10Yr

    18.06%

  • Rev Fwd 2Yr

    8.72%

  • EBITDA Fwd 2Yr

    2.89%

  • EPS Fwd 2Yr

    5.25%

  • EPS LT Growth Est

    12.38%

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Revenues

3,047.6

4,160.7

6,202.8

7,573.4

8,930.7

9,654.2

Other Revenues, Total

—

2.1

2.9

1.0

—

—

Total Revenues

3,047.6

4,162.8

6,205.7

7,574.4

8,930.7

9,654.2

Total Revenues % Chg.

22.5%

36.6%

49.1%

22.1%

17.9%

11.0%

Cost of Goods Sold, Total

1,826.0

2,302.3

2,381.2

2,842.0

3,607.6

3,706.8

Gross Profit

1,221.6

1,860.5

3,824.5

4,732.4

5,323.1

5,947.4

Selling General & Admin Expenses, Total

557.6

658.5

770.5

840.1

944.7

1,034.9

R&D Expenses

—

—

—

—

—

503.1

Other Operating Expenses, Total

557.6

658.5

770.5

840.1

944.7

1,538.0

Operating Income

664.0

1,202.0

3,054.0

3,892.3

4,378.4

4,409.4

Interest Expense, Total

-72.5

-58.5

-58.2

-61.5

-54.8

-45.1

Interest And Investment Income

38.4

63.7

22.2

4.9

144.6

521.2

Net Interest Expenses

-34.1

5.2

-36.0

-56.6

89.8

476.1

Currency Exchange Gains (Loss)

-1.1

-5.2

-16.1

-13.9

-15.1

6.0

Other Non Operating Income (Expenses)

-2.2

-0.2

0.8

1.7

-0.6

-43.9

EBT, Excl. Unusual Items

626.5

1,201.8

3,002.7

3,823.5

4,452.5

4,847.6

Restructuring Charges

0.2

—

—

—

—

—

Gain (Loss) On Sale Of Investments

2.6

197.6

311.9

17.1

-149.1

-6.2

Gain (Loss) On Sale Of Assets

—

—

—

—

—

—

Asset Writedown

-29.0

—

—

—

-13.0

—

In Process R&D Expenses

—

—

-184.6

-1,113.3

-115.5

-531.9

Other Unusual Items

—

-4.5

-13.1

3.1

57.5

-0.5

EBT, Incl. Unusual Items

600.2

1,394.9

3,116.9

2,730.4

4,232.4

4,309.0

Income Tax Expense

-1,486.9

218.1

405.2

388.3

910.4

839.3

Earnings From Continuing Operations

2,087.1

1,176.8

2,711.7

2,342.1

3,322.0

3,469.7

Earnings Of Discontinued Operations

—

—

—

—

—

—

Minority Interest

9.8

—

—

—

—

—

Net Income

2,096.9

1,176.8

2,711.7

2,342.1

3,322.0

3,469.7

Preferred Dividend and Other Adjustments

0.5

—

—

—

—

—

Net Income to Common Incl Extra Items

2,096.4

1,176.8

2,711.7

2,342.1

3,322.0

3,469.7

Net Income to Common Excl. Extra Items

2,096.4

1,176.8

2,711.7

2,342.1

3,322.0

3,469.7

Total Shares Outstanding

255.2

259.0

259.9

254.5

257.0

257.8

Weighted Avg. Shares Outstanding

254.3

256.7

259.8

257.7

256.1

257.5

Weighted Avg. Shares Outstanding Dil

259.2

260.7

263.4

259.9

259.1

260.4

EPS

8.2

4.6

10.4

9.1

13.0

13.5

EPS Diluted

8.1

4.5

10.3

9.0

12.8

13.3

EBITDA

736.4

1,308.9

3,163.5

4,017.9

4,526.7

4,570.1